Company / Cost of Revenue
Niagen Bioscience, Inc. Cost of Revenue History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cost of Revenue
$46.2M
FY2025
5-year range
$24.0M / $46.2M
FY2021-FY2025
Trend
+41.0%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cost of Revenue has increased for 5 consecutive years, from $21M in FY2020 to $46M in FY2025.
Based on SEC 10-K filings.
$46M in FY2025 with a 5-year CAGR of +17.6%.
Increased from $29M to $46M over the past 2 years.
Cost of Revenue over time
Growth rates
- 3-Year CAGR
- +21.2%
- 5-Year CAGR
- +17.6%
- 10-Year CAGR
- -
Key checks
Key Insights
- Niagen Bioscience, Inc.'s cost of revenue has grown for 5 consecutive years.
- 5-year CAGR of +17.6%, indicating consistent growth.
- In FY2025, cost of revenue increased 41.0% year-over-year.
- Lowest cost of revenue in the period was in FY2018.
Company context
Key Data Points
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cost of RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $46.2M | +41.0% |
| FY2024 | $32.8M | +12.1% |
| FY2023 | $29.3M | +12.7% |
| FY2022 | $26.0M | +8.2% |
| FY2021 | $24.0M | +16.9% |
| FY2020 | $20.5M | +0.0% |
| FY2019 | $20.5M | +91.4% |
| FY2018 | $10.7M | +0.0% |
| FY2017 | $10.7M | -4.9% |
| FY2016 | $11.3M | +8.9% |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026